sulfasalazine and Spondylitis, Ankylosing studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.

Research Excerpts

Excerpt	Relevance	Reference
"To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years."	9.12	Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. ( Alten, R; Baraliakos, X; Baumgaertner, M; Beck, E; Brandt, J; Braun, J; Burmester, G; Ebner, W; Gömör, B; Grasedyck, K; Haibel, H; Hammer, M; Hermann, J; Krause, A; Mielke, F; Sieper, J; Tony, HP; Zeidler, H; Zochling, J, 2006)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."	7.83	Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"In an attempt to estimate the frequency of folate deficiency and haemolysis in a group of 25 outpatients with arthritis treated with sulphasalazine (SASP), haematological measurements, including plasma total homocysteine (tHcy) which is a sensitive marker of folate deficiency, serum folate (S-folate), erythrocyte (RBC) folate, S-cobalamin and routine indices of haemolysis were performed."	7.69	Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. ( Ekelund, S; Krogh Jensen, M; Svendsen, L, 1996)
"Patients with axSpA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4, were recruited."	5.72	Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA. ( Eklund, K; Kaijasilta, JP; Kauppi, MJ; Kerola, AM; Kerola, T; Koivu, H; Loimaala, A; Nieminen, TVM; Relas, H; Schildt, J; Tuompo, R, 2022)
"Celecoxib was neutral regarding CVD risk in AS patients."	5.46	Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
" Current guidelines suggest sulfasalazine (SSZ) treatment as initial therapy for the management of patients with AS with peripheral arthritis versus therapy with biologics."	5.16	Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. ( Braun, J; Dimic, A; Freundlich, B; Koenig, AS; Pavelka, K; Ramos-Remus, C; Vlahos, B, 2012)
"To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years."	5.12	Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. ( Alten, R; Baraliakos, X; Baumgaertner, M; Beck, E; Brandt, J; Braun, J; Burmester, G; Ebner, W; Gömör, B; Grasedyck, K; Haibel, H; Hammer, M; Hermann, J; Krause, A; Mielke, F; Sieper, J; Tony, HP; Zeidler, H; Zochling, J, 2006)
"Out of 1283 patients (etanercept, n = 867; sulfasalazine, n = 187; placebo, n = 229), improvement in nocturnal back pain was a significant predictor of improvement in fatigue."	4.89	Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. ( Hammoudeh, M; Koenig, AS; Li, W; Stewart, VM; Zack, DJ, 2013)
"Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial."	4.77	Treatment of the seronegative spondyloarthropathies with sulfasalazine. ( Comer, SS; Erdman, WA; Lee, E; Lipsky, PE; Zwillich, SH, 1988)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."	3.83	Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"Sulfasalazine has no clinically relevant benefit in patients with ankylosing spondylitis."	3.80	[Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies]. ( Droste, U; Gromnica-Ihle, E; Milleck, D; Schmidt, WA; Wierth, S, 2002)
"Sulfasalazine is a safe and effective drug in the short term treatment of AS."	3.76	Meta-analysis of sulfasalazine in ankylosing spondylitis. ( Atra, E; Ferraz, MB; Goldsmith, CH; Tugwell, P, 1990)
"In an attempt to estimate the frequency of folate deficiency and haemolysis in a group of 25 outpatients with arthritis treated with sulphasalazine (SASP), haematological measurements, including plasma total homocysteine (tHcy) which is a sensitive marker of folate deficiency, serum folate (S-folate), erythrocyte (RBC) folate, S-cobalamin and routine indices of haemolysis were performed."	3.69	Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. ( Ekelund, S; Krogh Jensen, M; Svendsen, L, 1996)
"Eligible patients had active ankylosing spondylitis, fulfilled modified New York criteria, were previously untreated with biological disease-modifying antirheumatic drugs, and had inadequate response to at least two or intolerance or contraindication to non-steroidal anti-inflammatory drugs."	2.90	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. ( Chu, AD; Deodhar, A; Everding, A; Kim, TH; Kishimoto, M; Maksymowych, WP; Pangan, AL; Sieper, J; Song, IH; Sui, Y; van den Bosch, F; van der Heijde, D; Wang, X, 2019)
"Lumbar lordosis was a significant predictor of clinical outcome in AS patients treated with anti-TNF-α."	2.90	Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine. ( Choi, SH; Goh, TS; Lee, JS; Shin, JK; Son, SM, 2019)
"The Bath ankylosing spondylitis disease activity index (BASDAI), nocturnal back pain (NBP), total back pain (TBP), patient global disease activity (PGDA), the Bath ankylosing spondylitis functional index (BASFI), and the Bath ankylosing spondylitis metrology index (BASMI) were measured at each time point."	2.87	Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial. ( Wang, Y; Xiao, X, 2018)
"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) were statistically calculated."	2.82	[Effect of Xinfeng Capsule on AS Patients and Their Serum Immunoglobulin Subtypes and Peripheral Lymphocyte Autophagy]. ( Cao, YX; Liu, J; Ruan, LP; Wan, L; Wang, SH; Wang, YL; Ye, WF, 2016)
"The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (1."	2.80	Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis. ( Dong, X; Liu, HY; Shi, TY; Zheng, Y, 2015)
"A post hoc analysis of data from the Ankylosing Spondylitis Study Comparing ENbrel and Sulfasalazine Dosed Weekly (ASCEND) study was performed using the Natural History Staggered Start (NHSS) method."	2.78	Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis. ( Hendrix, S; Koenig, A; Li, W; Singh, A, 2013)
" Using data from the randomized double-blind Ankylosing Spondylitis Study Comparing Enbrel with Sulfasalazine Dosed Weekly (ASCEND) trial, we tested ASDAS validity and assessed its capacity to discriminate between treatment effects and change-from-baseline improvements."	2.77	Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. ( Braun, J; Dougados, M; Koenig, AS; Pedersen, R; Sieper, J; Szumski, A; van der Heijde, D, 2012)
" Serious adverse events rarely occurred, and the rate of serious adverse events did not differ between groups."	2.76	Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. ( Braun, J; Burgos-Vargas, R; Freundlich, B; Huang, F; Koenig, AS; van der Horst-Bruinsma, IE; Vlahos, B, 2011)
"TGP treatment combined with SSZ shows favorable effect on AS with less and milder adverse reaction."	2.73	[Clinical observation on total glucosides of paeony combined with sulfasalazine in treatment of ankylosing spondylitis]. ( Bian, H; Wang, JP; Wang, SL, 2007)
"Sulfasalazine treatment was not found effective on enthesal abnormalities of IRD patients."	2.73	The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. ( Duyur Cakit, B; Erdem, HR; Genc, H; Kacar, M; Nacir, B; Saracoglu, M, 2007)
"Methotrexate treatment may be useful in ankylosing spondylitis, but a combined treatment might be indicated for patients with peripheral arthritis."	2.69	Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A; Maleknia, T; Pacor, ML, 2000)
"To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy."	2.68	Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. ( Alepa, FP; Anderson, RJ; Blackburn, WD; Budiman-Mak, E; Buxbaum, J; Cannon, GW; Clegg, DO; Cohen, MR; Cush, JJ; Haakenson, CM; Henderson, WG; Luggen, ME; Mahowald, ML; Makkena, R; Manaster, BJ; Mejias, E; Reda, DJ; Schumacher, HR; Silverman, SL; Taylor, T; Vasey, FB; Ward, JR; Ward, RH; Weisman, MH, 1996)
"Treatment with sulfasalazine normalized these alterations."	2.67	Increased jejunal secretory IgA and IgM in ankylosing spondylitis: normalization after treatment with sulfasalazine. ( Brandtzaeg, P; Feltelius, N; Hällgren, R; Hvatum, M; Knutson, L, 1994)
"Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking."	2.66	Sulphasalazine in ankylosing spondylitis. ( Feltelius, N; Hällgren, R, 1986)
"Thus 60 patients with active ankylosing spondylitis without peripheral arthritis or gastrointestinal symptoms were randomly allocated to one of two therapeutic groups."	2.66	Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. ( Amor, B; Boumier, P; Dougados, M, 1986)
"Eighty-five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine (less than or equal to 3 gm/day, mean 2."	2.66	Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. ( Lehtinen, K; Leirisalo-Repo, M; Luukkainen, R; Mutru, O; Nissilä, M; Yli-Kerttula, U, 1988)
"Major outcomes included: pain, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis function index (BASFI), Bath ankylosing spondylitis metrology index (BASMI), radiographic progression, total number of withdrawals due to adverse events, and serious adverse events."	2.50	Sulfasalazine for ankylosing spondylitis. ( Chen, J; Lin, S; Liu, C, 2014)
"A FREQUENT AFFECTION: Ankylosing spondylitis is a chronic inflammatory rheumatism usually affecting young adults and characterized by an inflammatory enthesiopathy progressing towards ossification and ankylosis."	2.42	[Ankylosing spondylitis]. ( El Maghraoui, A, 2004)
"Management of ankylosing spondylitis (AS) is challenged by the progressive nature of the disease."	2.41	Conventional treatments for ankylosing spondylitis. ( Brandt, J; Dijkmans, B; Dougados, M; Khan, M; Maksymowych, W; van der Linden, S, 2002)
"Sulfasalazine has proven to be effective in such cases, leading to improvement in clinical and laboratory indices of disease activity."	2.40	Current guidelines for the drug treatment of ankylosing spondylitis. ( Toussirot, E; Wendling, D, 1998)
"Sulfasalazine has been evaluated by several groups of investigators in ankylosing spondylitis and psoriatic arthritis."	2.38	Medical and surgical treatment of seronegative spondyloarthropathies. ( Kozin, F, 1991)
"Patients with axSpA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4, were recruited."	1.72	Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA. ( Eklund, K; Kaijasilta, JP; Kauppi, MJ; Kerola, AM; Kerola, T; Koivu, H; Loimaala, A; Nieminen, TVM; Relas, H; Schildt, J; Tuompo, R, 2022)
"Twenty-four patients with cold, dampness, obstructive ankylosing spondylitis were treated with sulfasalazine and sulfasalazine in combination with moxibustion for 3 weeks."	1.56	Effects of sulfasalazine combined with moxibustion methods on patients with cold-dampness obstruction type ankylosing spondylitis. ( Liao, WJ; Liu, HF; Song, FJ, 2020)
"Sulfasalazine (SSZ), which has an arylamine sulfonamide structure, is an anti-inflammatory drug used in the treatment of many rheumatic diseases."	1.46	Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases. ( Cildag, S; Senturk, T, 2017)
"Celecoxib was neutral regarding CVD risk in AS patients."	1.46	Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017)
" Short course IFX dosing followed by continuation of MTX and SSZ combination can prolong time to disease flare and decrease requirement for additional IFX dose in SpA."	1.46	TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis. ( Danda, D; Nair, AM; Sandhya, P; Yadav, B, 2017)
"Sulfasalazine (SSA) is a common medication used for treatment of patients with AS."	1.42	Sulfasalazine Treatment Suppresses the Formation of HLA-B27 Heavy Chain Homodimer in Patients with Ankylosing Spondylitis. ( Huang, HB; Huang, HL; Huang, KY; Lai, NS; Liu, SQ; Lu, MC; Yu, HC, 2015)
"Data on lymphoma risk in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are scarce."	1.40	Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. ( Askling, J; Backlin, C; Baecklund, E; Eriksson, JK; Feltelius, N; Hellgren, K; Smedby, KE; Sundstrom, C, 2014)
"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were calculated, and sedimentation rate and C-reactive protein (CRP) levels measured."	1.38	Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis. ( Çakmak, VA; Capkin, E; Karkucak, M; Kose, MM; Tosun, M; Turkyilmaz, AK, 2012)
"Optic neuritis is rarely the first symptom of AS."	1.37	Ankylosing spondylitis presented as unilateral optic neuritis in a young woman. ( Chen, JT; Chou, YS; Lu, DW, 2011)
"Clinical features, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were noted at baseline (pre-infliximab), 1 month, 3 months and last follow-up after last dose of infliximab infusion."	1.37	Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy--experience from a tertiary care teaching hospital in South India. ( Danda, D; Gattani, A; Mathew, J; Sandhya, P, 2011)
"Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, progressive, systemic inflammatory rheumatic diseases that lead to serious disability."	1.35	Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. ( Akbulut, L; Altay, Z; Ataman, S; Aydoğ, E; Bal, A; Bodur, H; Delialioğlu, SU; Evcik, D; Günaydin, R; Gürsoy, S; Kavuncu, V; Kaya, T; Kocabaş, H; Kotevoğlu, N; Kuran, B; Madenci, E; Olmez, N; Ozel, S; Uğurlu, H; Yazgan, P, 2008)
"Sacroiliitis is an important sign of spondylarthritis (SpA) of which the prototype disease is ankylosing spondylitis."	1.35	Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. ( Argin, M; Gumusdis, G; Kabasakal, Y; Kitapcioglu, G; Taylan, A; Yargucu, F, 2009)
"Herein, we present an unusual case with Ankylosing spondylitis (AS) and autoimmune thyroiditis associated with TS."	1.34	Ankylosing spondylitis in a patient with Turner syndrome: a case report. ( Armagan, O; Dinc, A; Ekim, A; Oner, C, 2007)
"Sjogren's syndrome and ankylosing spondylitis can occur either alone or in conjunction with other disorders."	1.33	Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report. ( Cakirbay, H; Capkin, E; Guler, M; Karkucak, M; Topbas, M; Tosun, M, 2005)
"The association of Crohn's disease and ankylosing spondylitis is described in up to 30% of cases."	1.33	Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease. ( Chira, R; Marinescu, C; Rednic, N; Rednic, S; Rogojan, L, 2006)
"In addition to patients with RA or MCTD, focal sialadenitis also affects a very high proportion of patients with AS or SpA."	1.31	Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease. ( Helenius, I; Helenius, LM; Hietanen, JH; Kautiainen, H; Lappalainen, M; Leirisalo-Repo, M; Lindqvist, C; Paimela, L; Piirainen, H; Suuronen, R, 2001)
"Four children with chronic arthritis (3 juvenile rheumatoid arthritis and 1 juvenile ankylosing spondylitis) and poorly controlled chronic uveitis, were given sulphasalazine (SASP) therapy for a mean period of 3."	1.30	Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. ( Hsieh, KH; Huang, JL; Hung, IJ, 1997)
" Adverse events occurred in 64% of all patients (highest 85% in AS and lowest 50% in ulcerative colitis, CU)."	1.29	Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. ( Laasila, K; Leirisalo-Repo, M, 1994)
"Cases of half sister and brother with ankylosing spondylitis (AS) in whom drug therapy with salazosulfapyridine (SASP) showed excellent effect were reported."	1.29	[Successful treatment with salazosulfapyridine in cases sister and brother with ankylosing spondylitis]. ( Irimajiri, S; Kohno, M; Matsuoka, Y, 1993)
" Moreover, 1 drug should be used in appropriate dosage before it is assumed to be inefficient."	1.28	Ankylosing spondylitis. Current drug treatment. ( Gran, JT; Husby, G, 1992)
"Twenty-two patients with active ankylosing spondylitis were investigated to assess the levels of specific serum IgG, IgA and IgM titres against Campylobacter jejuni/coli before and during treatment with sulfasalazine."	1.28	No signs of Campylobacter jejuni/coli-related antibodies in patients with active ankylosing spondylitis. ( Andreasen, JJ; Helin, P; Ringsdal, VS, 1991)
"Drug studies in ankylosing spondylitis (AS) are usually short term, in highly selected patients at academic centers."	1.28	A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. ( Calin, A; Elswood, J, 1990)
"Twenty-nine patients with ankylosing spondylitis (AS) were studied in an attempt to evaluate the role of T lymphocytes in this disease and a possible influence of treatment."	1.27	T lymphocytes in ankylosing spondylitis and the influence of sulphasalazine treatment. ( Feltelius, N; Hällgren, R; Sjöberg, O, 1987)

Research

Studies (164)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (11.59)	18.7374
1990's	44 (26.83)	18.2507
2000's	52 (31.71)	29.6817
2010's	43 (26.22)	24.3611
2020's	6 (3.66)	2.80

Authors	Studies
Kaijasilta, JP	1
Kerola, AM	1
Tuompo, R	1
Relas, H	1
Loimaala, A	1
Koivu, H	1
Schildt, J	1
Kerola, T	1
Eklund, K	1
Kauppi, MJ	1
Nieminen, TVM	1
Armağan, B	1
Atalar, E	1
Güven, SC	1
Özdemir, B	1
Konak, HE	1
Akyüz Dağlı, P	1
Erden, A	1
Gök, K	1
Maraş, Y	1
Doğan, İ	1
Küçükşahin, O	1
Erten, Ş	2
Omma, A	1
van der Heijde, D	2
Song, IH	2
Pangan, AL	1
Deodhar, A	1
van den Bosch, F	1
Maksymowych, WP	1
Kim, TH	1
Kishimoto, M	1
Everding, A	1
Sui, Y	1
Wang, X	1
Chu, AD	1
Sieper, J	9
Man, S	1
Ji, X	1
Wang, Y	2
Ma, Y	1
Hu, Z	1
Zhu, J	1
Zhang, J	1
Huang, F	3
Huang, D	1
Liu, J	3
Zong, RK	1
Wan, L	3
Ganapati, A	1
Gowri, M	1
Antonisamy, B	1
Danda, D	3
Liao, WJ	1
Song, FJ	1
Liu, HF	1
Nair, AM	1
Sandhya, P	2
Yadav, B	1
Khanna Sharma, S	1
Kadiyala, V	1
Naidu, G	1
Dhir, V	1
Chen, Z	1
Pang, G	1
Tian, Y	1
Tang, D	1
Tian, C	1
Zhang, C	1
Zhang, Y	1
Xiao, X	1
Son, SM	1
Choi, SH	1
Shin, JK	1
Goh, TS	1
Lee, JS	1
Dhakad, U	1
Das, SK	1
Hammoudeh, M	1
Zack, DJ	2
Li, W	2
Stewart, VM	1
Koenig, AS	6
Hendrix, S	1
Koenig, A	1
Singh, A	1
Hellgren, K	1
Smedby, KE	1
Backlin, C	1
Sundstrom, C	1
Feltelius, N	7
Eriksson, JK	1
Baecklund, E	1
Askling, J	2
Dong, X	1
Zheng, Y	1
Shi, TY	1
Liu, HY	1
Qi, Y	1
Zheng, L	1
Cao, Y	1
Hou, ZD	1
Xiao, ZY	1
Gong, Y	1
Zhang, YP	1
Zeng, QY	1
Chen, J	3
Lin, S	1
Liu, C	3
Xiao, P	1
Pang, C	1
Zhu, X	1
Wu, X	1
Lie, E	1
Kristensen, LE	1
Forsblad-d'Elia, H	1
Zverkova-Sandström, T	1
Jacobsson, LT	1
Landewé, RB	1
Baraliakos, X	2
Jones, H	1
Szumski, A	4
Collier, D	1
Bananis, E	2
Agarwal, NN	1
Patil, D	1
Nagendra, S	1
Jadhav, SM	1
Yu, HC	1
Lu, MC	1
Huang, KY	1
Huang, HL	1
Liu, SQ	1
Huang, HB	1
Lai, NS	1
Suh, YS	1
Kim, HO	1
Cheon, YH	1
Jo, W	1
Hong, J	1
Lee, SI	1
Damjanov, N	1
Shehhi, WA	1
Kotak, S	1
Burgos-Vargas, R	3
Shirazy, K	1
Llamado, LJ	1
Mahgoub, E	1
Ye, WF	1
Cao, YX	1
Wang, SH	1
Wang, YL	1
Ruan, LP	1
Wu, LC	1
Leong, PY	2
Yeo, KJ	2
Li, TY	1
Wang, YH	2
Chiou, JY	2
Wei, JC	3
Tam, HW	1
Chen, CH	1
Li, YC	1
Ma, CM	1
Cildag, S	1
Senturk, T	1
Akar, S	1
Birlik, M	1
Sari, I	2
Onen, F	1
Akkoc, N	1
Başkan, BM	1
Sivas, F	1
Aktekin, LA	1
Doğan, YP	1
Ozoran, K	1
Bodur, H	2
Goh, L	1
Samanta, A	1
Kabasakal, Y	1
Kitapcioglu, G	1
Yargucu, F	1
Taylan, A	2
Argin, M	1
Gumusdis, G	1
Madsen, OR	1
Egsmose, C	1
Yülek, F	1
Orhan, N	1
Simsek, S	1
Alacacioglu, A	1
Kebapcilar, L	1
Bilgir, O	1
Yildiz, Y	1
Yuksel, A	1
Kozaci, DL	1
Chen, LA	1
Su, LH	1
Chang, YJ	1
Hsu, YL	1
Tsai, TH	1
Kang, KY	1
Lee, KY	1
Kwok, SK	1
Ju, JH	1
Park, KS	1
Hong, YS	1
Kim, HY	1
Park, SH	1
Tadmor, T	1
Rimar, D	1
Rozenbaum, M	1
Vadasz, Z	1
Attias, D	1
Capkin, E	2
Karkucak, M	2
Kose, MM	1
Çakmak, VA	1
Turkyilmaz, AK	1
Tosun, M	2
Mathew, J	1
Gattani, A	1
Chou, YS	1
Lu, DW	1
Chen, JT	1
Daoulah, A	1
Alqahtani, AA	1
Ocheltree, SR	1
Alhabib, A	1
Ocheltree, AR	1
Ward, MM	2
Braun, J	8
van der Horst-Bruinsma, IE	2
Vlahos, B	2
Freundlich, B	3
Pavelka, K	1
Ramos-Remus, C	1
Dimic, A	1
Althoff, CE	1
Haibel, H	2
Hermann, KG	1
Poddubnyy, D	1
Listing, J	1
Weiß, A	1
Djacenko, S	1
Burmester, GR	2
Bohl-Bühler, M	1
Rudwaleit, M	1
Dougados, M	8
Pedersen, R	1
Tay, SH	1
Lateef, A	1
Cheung, PP	1
Can, M	1
Aydın, SZ	1
Niğdelioğlu, A	1
Atagündüz, P	1
Direskeneli, H	1
Kuzis, S	1
Vázquez-Mellado, J	1
Pacheco-Tena, C	1
Hernández-Garduño, A	1
Goycochea-Robles, MV	1
Tsai, WC	1
Chen, CJ	1
Yen, JH	1
Liu, HW	1
Dijkmans, B	2
Khan, M	1
Maksymowych, W	1
van der Linden, S	1
Brandt, J	2
Druesne, L	1
Verdonck, A	1
Derambure, V	1
Kadri, K	1
Chassagne, P	1
Bercoff, E	1
Doucet, J	1
Marino, C	1
McDonald, E	1
Corapci, I	1
Armagan, O	2
Tascioglu, F	1
Oner, C	2
Olivieri, I	2
Scarano, E	1
Ciancio, G	1
Padula, A	1
Benjamin, M	1
El Maghraoui, A	1
Cakirbay, H	1
Guler, M	1
Topbas, M	1
Savastano, M	1
Marioni, G	1
Bernini, G	1
Punzi, L	1
Ayhan-Ardic, FF	1
Oken, O	1
Yorgancioglu, ZR	1
Ustun, N	1
Gokharman, FD	1
Boulos, P	1
Macleod, SM	1
Hunsche, E	1
Ulusoy, V	1
Ateş, A	1
Ciçekcioğlu, H	1
Avcioğlu, Y	1
Karaaslan, Y	1
Schatteman, L	1
Gyselbrecht, L	1
De Clercq, L	1
Mielants, H	4
Zochling, J	1
Alten, R	1
Burmester, G	1
Grasedyck, K	1
Hammer, M	1
Krause, A	1
Mielke, F	1
Tony, HP	1
Ebner, W	1
Gömör, B	2
Hermann, J	1
Zeidler, H	2
Beck, E	1
Baumgaertner, M	1
Jia, J	1
Wang, Q	1
Zhang, T	1
Li, J	1
Narváez, J	1
Montala, N	1
Busquets-Pérez, N	1
Nolla, JM	1
Valverde, J	1
Sakellariou, GT	1
Kakavouli, G	1
Chatzigiannis, I	1
Jan, MS	1
Yu, CT	1
Huang, YC	1
Yang, CC	1
Tsou, HK	1
Lee, HS	1
Chou, CT	1
Tsay, G	1
Chou, MC	1
Scherer, HU	1
Genc, H	1
Duyur Cakit, B	1
Nacir, B	1
Saracoglu, M	1
Kacar, M	1
Erdem, HR	1
Rednic, S	1
Marinescu, C	1
Chira, R	1
Rogojan, L	1
Rednic, N	1
Wang, SL	1
Wang, JP	1
Bian, H	1
Ekim, A	1
Dinc, A	1
Adebayo, D	1
Popat, R	1
Thjodleifsson, B	1
Bjarnason, I	1
Malaviya, AN	1
Kapoor, S	1
Garg, S	1
Ahmad, I	1
Raja, RR	1
Zhao, FT	1
Zhao, H	1
Chogle, AR	1
Mishra, H	1
Chakravarty, A	1
Goodemote, P	1
Jamieson, B	1
Hoffman, R	1
Ataman, S	1
Akbulut, L	1
Evcik, D	1
Kavuncu, V	1
Kaya, T	1
Günaydin, R	1
Kuran, B	1
Kotevoğlu, N	1
Bal, A	1
Aydoğ, E	1
Altay, Z	1
Uğurlu, H	1
Kocabaş, H	1
Olmez, N	1
Yazgan, P	1
Gürsoy, S	1
Madenci, E	1
Ozel, S	1
Delialioğlu, SU	1
Janowitz, HD	1
Sachar, DB	1
Amor, B	3
Kahan, A	1
Delrieu, F	1
Küster, W	1
Lenz, W	1
Veys, EM	3
Cuvelier, C	1
De Vos, M	1
Helliwell, PS	2
Harley, JB	1
Scofield, RH	1
Creemers, MC	1
Franssen, MJ	1
van de Putte, LB	1
Gribnau, FW	1
van Riel, PL	1
Mäki-Ikola, O	3
Nissilä, M	5
Lehtinen, K	5
Leirisalo-Repo, M	8
Granfors, K	4
vam der Linden, S	1
Huitfeldt, B	2
Juhlin, R	1
Veys, E	1
Kvien, TK	1
Toivanen, P	2
Laasila, K	1
Hvatum, M	1
Brandtzaeg, P	1
Knutson, L	1
Hällgren, R	6
Lahesmaa, R	1
Kohno, M	1
Matsuoka, Y	1
Irimajiri, S	1
De Keyser, F	1
Praet, J	1
Goemaere, S	1
Kirwan, J	1
Edwards, A	1
Thompson, P	1
Currey, H	1
Magnus, JH	1
Elverland, HH	1
Olsen, EG	1
Husby, G	2
Taggart, A	1
Gardiner, P	1
McEvoy, F	1
Hopkins, R	1
Bird, H	1
Krogh Jensen, M	1
Ekelund, S	1
Svendsen, L	1
Clegg, DO	2
Reda, DJ	2
Weisman, MH	1
Blackburn, WD	1
Cush, JJ	1
Cannon, GW	1
Mahowald, ML	1
Schumacher, HR	1
Taylor, T	1
Budiman-Mak, E	1
Cohen, MR	1
Vasey, FB	1
Luggen, ME	1
Mejias, E	1
Silverman, SL	1
Makkena, R	1
Alepa, FP	1
Buxbaum, J	1
Haakenson, CM	1
Ward, RH	1
Manaster, BJ	1
Anderson, RJ	1
Ward, JR	1
Henderson, WG	1
Faucher, C	1
Albert, C	1
Beaufils, H	1
Jouanneau, C	1
Dupouet, L	1
Huang, JL	2
Hung, IJ	1
Hsieh, KH	1
Toussirot, E	1
Wendling, D	1
Dubost, JJ	1
Soubrier, M	1
Sauvezie, B	1
Chen, LC	1
Gran, JT	2
Ostensen, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis[NCT03178487]	Phase 2	187 participants (Actual)	Interventional	2017-10-24	Completed
A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis[NCT00247962]	Phase 4	566 participants (Actual)	Interventional	2005-12-31	Completed
Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study[NCT00506896]	Phase 2	60 participants (Actual)	Interventional	2004-07-31	Completed
Interventional Study: Administration of Intraarticular Injection of Infliximab in Patients With Inflammatory Arthritis Who Failed Intraarticular Injection of Corticosteroids[NCT00521963]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2010-03-31	Withdrawn (stopped due to poor accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:~Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])~Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])~Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])~Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])~High-sensitivity C-reactive protein (hs-CRP) in mg/L.~The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.54
Upadacitinib 15 mg	-1.45

"The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).~Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in ASAS Health Index (HI) at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-2.67
Upadacitinib 15 mg	-4.20

"The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as I agree (score = 1) or I disagree (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-1.38
Upadacitinib 15 mg	-2.75

The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement. (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-1.30
Upadacitinib 15 mg	-2.29

"The BASMI is a composite score based on 5 direct measurements of spinal mobility:~cervical rotation (measured in degrees),~tragus to wall distance (in centimeters [cm])~lumbar side flexion (in cm),~lumbar flexion (modified Schober's) (in cm) and~intermalleolar distance (in cm).~Each measurement is converted to a linear score between 0 and 10. The total BASMI score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.14
Upadacitinib 15 mg	-0.37

The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-1.41
Upadacitinib 15 mg	-2.25

"In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.~Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.~The total maximum score for all SI joints across 6 slices is 72." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14 - Supplementary Analysis

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.22
Upadacitinib 15 mg	-3.91

"In the SPARCC MRI assessment of the sacroiliac joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.~Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum score for all SI joints across 6 slices is 72.~A supplemental post-hoc SPARCC MRI analysis was done to include all MRI data collected at nominal visits at Baseline and Week 14." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in SPARCC MRI Score for the Spine at Week 14 - Supplementary Analysis

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.90
Upadacitinib 15 mg	-3.45

"In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six DVUs representing the 6 most abnormal DVUs were selected to calculate the SPARCC MRI spine score. For each DVU, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least 1 quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108.~A supplemental post-hoc SPARCC MRI analysis included all MRI data collected at nominal visits at Baseline and Week 14." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for the Spine at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.65
Upadacitinib 15 mg	-6.86

"In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.~Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.~The maximum (worst) overall score for all 6 DVUs is 108." (NCT03178487)
Timeframe: Baseline and Week 14

Change From Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment at Week 14

Intervention	score on a scale (Least Squares Mean)
Placebo	-0.22
Upadacitinib 15 mg	-6.93

The Work Productivity and Activity Impairment Questionnaire: Axial Spondyloarthritis, Version 2.0 (WPAI-Axial Spondyloarthritis) measures the effect of overall health and specific symptoms on productivity at work and outside of work. It consists of 6 questions. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Overall Work Impairment indicates the percentage of overall work impairment due to health problems. A negative change from Baseline indicates improvement. (NCT03178487)
Timeframe: Baseline and Week 14

Percentage of Participants Achieving an ASAS 20 Response at Week 14

Intervention	percent impairment (Least Squares Mean)
Placebo	-12.60
Upadacitinib 15 mg	-18.11

"ASAS 20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:~Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);~Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);~Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);~Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration)." (NCT03178487)
Timeframe: Baseline and Week 14

Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) Partial Remission

Intervention	percentage of participants (Number)
Placebo	40.4
Upadacitinib 15 mg	64.5

"ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:~Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);~Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);~Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);~Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration)." (NCT03178487)
Timeframe: Week 14

Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14

Intervention	percentage of participants (Number)
Placebo	1.1
Upadacitinib 15 mg	19.4

"ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:~Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);~Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);~Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);~Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration)." (NCT03178487)
Timeframe: Baseline and Week 14

Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14

Intervention	percentage of participants (Number)
Placebo	25.5
Upadacitinib 15 mg	51.6

"The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.~A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score." (NCT03178487)
Timeframe: Baseline and Week 14

Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)

Intervention	percentage of participants (Number)
Placebo	23.4
Upadacitinib 15 mg	45.2

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) participants ASAS = 4 domains: participant global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement from baseline and an improvement ≥ 10 units on a 0-100 scale (0=no disease activity; 100=high disease activity) for ≥ 3 domains, and no worsening in remaining domain. (NCT00247962)
Timeframe: 16 weeks

Ankylosing Spondylitis Quality of Life (ASQoL) Total Score Change From Baseline

Intervention	participants (Number)
Etanercept	287
Sulphasalazine	99

"ASQoL is a questionnaire to assess disease specific quality of life. It consists of 18 statements that are relevant to the physical and mental conditions for a patient with Ankylosing Spondylitis (AS). Each statement is answered by the patients as a Yes (scored as 1) or No (scored as 0). All item scores are summed to give a total score. Scores can range from 0 (good QoL) to 18 (poor QoL)." (NCT00247962)
Timeframe: Baseline and 16 Weeks

Intervention	units on a scale (Mean)
	Baseline	Week 16
Etanercept	11.03	6.21
Sulphasalazine	11.32	9.06

Article	Year
Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. The Journal of international medical research, 2013, Volume: 41, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; C-Reactive Protein; Etanercept; Fatigue;	2013
Sulfasalazine for ankylosing spondylitis. The Cochrane database of systematic reviews, 2014, Nov-27, Issue:11 Topics: Antirheumatic Agents; Humans; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfas	2014
Ankylosing spondylitis associated with primary aldosteronism in a middle-aged woman. The Korean journal of internal medicine, 2017, Volume: 32, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Biological Products; Biomarkers; Drug	2017
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatology international, 2009, Volume: 29, Issue:10 Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona	2009
[Disease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis]. Ugeskrift for laeger, 2009, Aug-10, Volume: 171, Issue:33 Topics: Antibodies, Monoclonal; Antirheumatic Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hu	2009
New-onset psoriasis associated with etanercept therapy. The Journal of dermatology, 2010, Volume: 37, Issue:4 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles	2010
An unusual case of ankylosing spondylitis presenting with severe anemia. Acta haematologica, 2010, Volume: 124, Issue:3 Topics: Adult; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Erythrocyte Transfusion; Humans; Male; Spond	2010
Conventional treatments for ankylosing spondylitis. Annals of the rheumatic diseases, 2002, Volume: 61 Suppl 3 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Azathioprine; Dipho	2002
[Ankylosing spondylitis]. Presse medicale (Paris, France : 1983), 2004, Nov-20, Volume: 33, Issue:20 Topics: Acquired Hyperostosis Syndrome; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A	2004
Sulfasalazine for ankylosing spondylitis. The Cochrane database of systematic reviews, 2005, Apr-18, Issue:2 Topics: Antirheumatic Agents; Humans; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfas	2005
Tinnitus and bilateral sensorineural hearing loss: ankylosing spondylitis or a side-effect of sulphasalazine treatment? Acta oto-laryngologica, 2005, Volume: 125, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Audiometry, Pure-Tone; Auditory Threshold; Follow-Up	2005
Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs, 2005, Volume: 65, Issue:15 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clinical	2005
Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. The Journal of rheumatology, 2006, Volume: 33, Issue:4 Topics: Antirheumatic Agents; Blood Sedimentation; Humans; Randomized Controlled Trials as Topic; Range of M	2006
[Biologicals in the treatment of rheumatic diseases]. Deutsche medizinische Wochenschrift (1946), 2006, Oct-13, Volume: 131, Issue:41 Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl	2006
Inflammatory bowel disease. Advances in internal medicine, 1982, Volume: 27 Topics: Adrenal Cortex Hormones; Adult; Child; Colectomy; Colitis, Ulcerative; Crohn Disease; Female; Humans	1982
[Crohn disease and ulcerative colitis. Frequency, familial occurrence and pregnancy course]. Ergebnisse der inneren Medizin und Kinderheilkunde, 1984, Volume: 53 Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Chromosome Mapping; Colitis, Ulcerati	1984
Current guidelines for the drug treatment of ankylosing spondylitis. Drugs, 1998, Volume: 56, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Immunosuppressive Agents; Penicillamine; Spondyliti	1998
[Treatment of refractory spondylarthropathies]. Presse medicale (Paris, France : 1983), 1998, Jan-31, Volume: 27, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroida	1998
Therapeutic aspects of spondyloarthropathies -- a review. Scandinavian journal of rheumatology, 1998, Volume: 27, Issue:5 Topics: Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Infectious; Chlamydia Infections; Chlamydia	1998
Spondyloarthritides in females. Bailliere's clinical rheumatology, 1998, Volume: 12, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Female; Genetic Counseling; HLA-B	1998
Psoriatic arthritis. Is something changing? Advances in experimental medicine and biology, 1999, Volume: 455 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Psoriatic; Cycl	1999
Juvenile spondyloarthropathies. Current opinion in rheumatology, 2000, Volume: 12, Issue:4 Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Reactive; Child; Female; Germany;	2000
New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. Annals of the rheumatic diseases, 2001, Volume: 60 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug Administ	2001
[New and old therapeutic options in ankylosing spondylitis--is there an indication for sulfasalazine?]. Zeitschrift fur Rheumatologie, 2002, Volume: 61, Issue:2 Topics: Antirheumatic Agents; Clinical Trials as Topic; Humans; Meta-Analysis as Topic; Spondylitis, Ankylos	2002
[Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies]. Zeitschrift fur Rheumatologie, 2002, Volume: 61, Issue:2 Topics: Activities of Daily Living; Adult; Antirheumatic Agents; C-Reactive Protein; Dose-Response Relations	2002
Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? Bailliere's clinical rheumatology, 1990, Volume: 4, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclopho	1990
Medical and surgical treatment of seronegative spondyloarthropathies. Current opinion in rheumatology, 1991, Volume: 3, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Behcet Syndrome; Humans; Joint Diseas	1991
[Advances in the research on antirheumatic drug: sulfasalazine]. Zhonghua nei ke za zhi, 1990, Volume: 29, Issue:4 Topics: Arthritis, Rheumatoid; Humans; Spondylitis, Ankylosing; Sulfasalazine	1990
Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of rheumatology, 1990, Volume: 17, Issue:11 Topics: Double-Blind Method; Humans; Meta-Analysis as Topic; Outcome and Process Assessment, Health Care; Pa	1990
[Sulfasalazine therapy in spondylarthritis ankylopoietica]. Orvosi hetilap, 1989, Jan-08, Volume: 130, Issue:2 Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Placebos; Spond	1989
[Experience in the use of salazopyrine EN in patients with spondylarthritis ankylopoietica and rheumatoid arthritis]. Orvosi hetilap, 1988, Sep-04, Volume: 129, Issue:36 Topics: Adult; Arthritis, Rheumatoid; Drug Combinations; Female; Glucosamine; Humans; Male; Middle Aged; Spo	1988
Treatment of the seronegative spondyloarthropathies with sulfasalazine. The Journal of rheumatology. Supplement, 1988, Volume: 16 Topics: Adolescent; Adult; Arthritis; Female; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Spondy	1988
Sulfasalazine in the rheumatic disease. Seminars in arthritis and rheumatism, 1988, Volume: 17, Issue:4 Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Central Nervous System; Chemical and Drug Induced Liver	1988

Article	Year
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet (London, England), 2019, 12-07, Volume: 394, Issue:10214 Topics: Adult; Antirheumatic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Co	2019
[Huangqin Qingre Chubi Capsules in improving oxidative stress of patients with ankylosing spondylitis via activating PPARγ mediated AMPK/FOXO3a pathway]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2020, Volume: 45, Issue:2 Topics: AMP-Activated Protein Kinases; Capsules; Drugs, Chinese Herbal; Forkhead Box Protein O3; Humans; Oxi	2020
A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. International journal of rheumatic diseases, 2018, Volume: 21, Issue:1 Topics: Adolescent; Adult; Antirheumatic Agents; Double-Blind Method; Female; Humans; India; Male; Middle Ag	2018
[Acupuncture assisted by dynamic moxibustion for adult ankylosing spondylitis at early-to-mid stage]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2016, Nov-12, Volume: 36, Issue:11 Topics: Acupuncture Points; Acupuncture Therapy; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-	2016
[Clinical observation of ankylosing spondylitis treated with moxibustion along the governor vessel and the conception vessel and salazosulfapyridine]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2016, Oct-12, Volume: 36, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Moxibustion; Spondylitis, Ankylosing; Sulfasalazine	2016
Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial. Medical science monitor : international medical journal of experimental and clinical research, 2018, May-08, Volume: 24 Topics: Celecoxib; Drugs, Chinese Herbal; Female; Humans; Male; Spondylitis, Ankylosing; Sulfasalazine; Trea	2018
Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2019, Volume: 28, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Protein; Drug Therap	2019
Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis. The Journal of international medical research, 2013, Volume: 41, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Humans; Immunoglobulin G; Models, Statistical;	2013
Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis. Clinical rheumatology, 2015, Volume: 34, Issue:5 Topics: Adult; Antirheumatic Agents; Blood Sedimentation; C-Reactive Protein; Etanercept; Humans; Infliximab	2015
[The effect of Xinfeng capsule treatment on the number of BTLA(+)T cells and oxidative stress of patients with ankylosing spondylitis]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2014, Volume: 30, Issue:10 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Catalase; Cytokines; Drugs, Ch	2014
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatology international, 2016, Volume: 36, Issue:5 Topics: Adult; Antirheumatic Agents; Asia; Double-Blind Method; Etanercept; Europe; Female; Humans; Latin Am	2016
[Effect of Xinfeng Capsule on AS Patients and Their Serum Immunoglobulin Subtypes and Peripheral Lymphocyte Autophagy]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2016, Volume: 36, Issue:3 Topics: Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Capsules; Drugs, Chinese Herbal; Humans; Immunog	2016
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis and rheumatism, 2011, Volume: 63, Issue:6 Topics: Adult; Antirheumatic Agents; Double-Blind Method; Etanercept; Female; Humans; Immunoglobulin G; Male	2011
Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. The Journal of rheumatology, 2012, Volume: 39, Issue:4 Topics: Adult; Antirheumatic Agents; Arthritis; Double-Blind Method; Etanercept; Female; Humans; Immunoglobu	2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Annals of the rheumatic diseases, 2012, Volume: 71, Issue:7 Topics: Antirheumatic Agents; Drug Substitution; Etanercept; Female; Humans; Immunoglobulin G; Magnetic Reso	2012
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford, England), 2012, Volume: 51, Issue:10 Topics: Adult; Antirheumatic Agents; Double-Blind Method; Etanercept; Female; Humans; Immunoglobulin G; Male	2012
Medication toxicity among patients with ankylosing spondylitis. Arthritis and rheumatism, 2002, Jun-15, Volume: 47, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Female; Humans; Longitudinal S	2002
A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Annals of the rheumatic diseases, 2002, Volume: 61, Issue:10 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Doub	2002
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Annals of the rheumatic diseases, 2006, Volume: 65, Issue:9 Topics: Adolescent; Adult; Antirheumatic Agents; Back Pain; Female; Humans; Male; Middle Aged; Severity of I	2006
Treatment of ankylosing spondylitis with medicated moxibustion plus salicylazosulfapyridine and methotrexate--a report of 30 cases. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2006, Volume: 26, Issue:1 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Female; Human	2006
The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clinical rheumatology, 2007, Volume: 26, Issue:7 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Female; Health Status; Hu	2007
[Clinical observation on total glucosides of paeony combined with sulfasalazine in treatment of ankylosing spondylitis]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:3 Topics: Adolescent; Adult; Antirheumatic Agents; Drug Therapy, Combination; Female; Glucosides; Humans; Male	2007
A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Adolescent; Adult; Antirheumatic Agents; Bone Density Conservation Agents; Diphosphonates; Drug Resi	2007
[Clinical study on treatment of patients with ankylosing spondylitis by Panlongqi tablet]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:6 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Drugs, Chines	2007
Methotrexate in severe ankylosing spondylitis: an open study. The Journal of rheumatology, 1995, Volume: 22, Issue:6 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Female; Humans; Male; Methotrexate; Middle Aged; Spondyl	1995
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis and rheumatism, 1995, Volume: 38, Issue:5 Topics: Adult; Arthritis, Psoriatic; Arthritis, Reactive; Double-Blind Method; Female; Humans; Male; Middle	1995
Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in the sera of patients with axial and peripheral form of ankylosing spondylitis. British journal of rheumatology, 1995, Volume: 34, Issue:5 Topics: Antibodies, Bacterial; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Humans; Immunoglobulin A	1995
Increased jejunal secretory IgA and IgM in ankylosing spondylitis: normalization after treatment with sulfasalazine. The Journal of rheumatology, 1994, Volume: 21, Issue:11 Topics: Adult; Aged; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin A; Immunoglobulin A, Secretor	1994
Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment. The Journal of rheumatology, 1994, Volume: 21, Issue:11 Topics: Adult; Antibodies, Bacterial; Double-Blind Method; Escherichia coli; Female; Follow-Up Studies; Huma	1994
The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. British journal of rheumatology, 1993, Volume: 32, Issue:8 Topics: Adult; Back Pain; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periarthritis; Prospective S	1993
Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis and rheumatism, 1996, Volume: 39, Issue:8 Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Binding Site	1996
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism, 1996, Volume: 39, Issue:12 Topics: Adult; Anti-Inflammatory Agents; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Pa	1996
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis and rheumatism, 1999, Volume: 42, Issue:11 Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Reactive; Double-Blind Method; Female;	1999
Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clinical rheumatology, 2000, Volume: 19, Issue:2 Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspartat	2000
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (London, England), 2000, Volume: 14 ( Pt 3A) Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood-Aqueous Barrier; Chronic	2000
[Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies]. Zeitschrift fur Rheumatologie, 2002, Volume: 61, Issue:2 Topics: Activities of Daily Living; Adult; Antirheumatic Agents; C-Reactive Protein; Dose-Response Relations	2002
Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clinical rheumatology, 1991, Volume: 10, Issue:1 Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Prote	1991
Sulphasalazine and ankylosing spondylitis. British journal of rheumatology, 1990, Volume: 29, Issue:1 Topics: Blood Sedimentation; Clinical Trials as Topic; Humans; Spondylitis, Ankylosing; Sulfasalazine	1990
A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. British journal of rheumatology, 1990, Volume: 29, Issue:1 Topics: Chronic Disease; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male; Pain; Spine; Spo	1990
Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of rheumatology, 1990, Volume: 17, Issue:11 Topics: Double-Blind Method; Humans; Meta-Analysis as Topic; Outcome and Process Assessment, Health Care; Pa	1990
[Sulfasalazine therapy in spondylarthritis ankylopoietica]. Orvosi hetilap, 1989, Jan-08, Volume: 130, Issue:2 Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Placebos; Spond	1989
Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. British journal of rheumatology, 1989, Volume: 28, Issue:5 Topics: Adult; alpha 1-Antitrypsin; Double-Blind Method; Female; Humans; Immunoglobulin A; Male; Middle Aged	1989
Sulphasalazine in ankylosing spondylitis. Annals of the rheumatic diseases, 1986, Volume: 45, Issue:5 Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haptoglobins; Humans; Male; Middle Age	1986
Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. British medical journal (Clinical research ed.), 1986, Oct-11, Volume: 293, Issue:6552 Topics: Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Spondylitis, Ankylosing; Sulfas	1986
[Treatment of ankylosing spondylitis with salazosulfapyridine. A controlled double-blind study in 60 patients]. Revue du rhumatisme et des maladies osteo-articulaires, 1987, Volume: 54, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Drug	1987
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis and rheumatism, 1988, Volume: 31, Issue:9 Topics: Analysis of Variance; Clinical Trials as Topic; Double-Blind Method; Drug Eruptions; Gastrointestina	1988
Sulfasalazine in the rheumatic disease. Seminars in arthritis and rheumatism, 1988, Volume: 17, Issue:4 Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Central Nervous System; Chemical and Drug Induced Liver	1988

Article	Year
Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA. Immunity, inflammation and disease, 2022, Volume: 10, Issue:2 Topics: Adalimumab; Aorta; Axial Spondyloarthritis; Humans; Inflammation; Positron Emission Tomography Compu	2022
Effects of sulfasalazine in axial spondyloarthritis on COVID-19 outcomes: real-life data from a single center. Immunopharmacology and immunotoxicology, 2023, Volume: 45, Issue:4 Topics: Axial Spondyloarthritis; Biological Products; COVID-19; Female; Humans; Male; Middle Aged; Retrospec	2023
Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China. Medical science monitor : international medical journal of experimental and clinical research, 2020, Jan-21, Volume: 26 Topics: Adult; Antirheumatic Agents; Biomarkers; Blood Sedimentation; C-Reactive Protein; China; Disease Pro	2020
Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study. Clinical rheumatology, 2021, Volume: 40, Issue:5 Topics: Antirheumatic Agents; Cohort Studies; Humans; Methotrexate; Prospective Studies; Spondylarthritis; S	2021
Effects of sulfasalazine combined with moxibustion methods on patients with cold-dampness obstruction type ankylosing spondylitis. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:3(Special) Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blood Sedimentation; C-Reactive Protein;	2020
TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis. Clinical rheumatology, 2017, Volume: 36, Issue:10 Topics: Adult; Cost Savings; Electronic Health Records; Female; Follow-Up Studies; Health Care Costs; Humans	2017
Andersson lesion in ankylosing spondylitis. BMJ case reports, 2013, Apr-03, Volume: 2013 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Back Pain; Bed Rest; Biopsy; Diagnosi	2013
Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Case-Control	2014
Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine. BMC pharmacology & toxicology, 2014, Nov-21, Volume: 15 Topics: Adolescent; Adult; Antirheumatic Agents; Arylamine N-Acetyltransferase; Asian People; Female; Genoty	2014
Clinical research for curing ankylosing spondylitis through combining etanercept, thalidomide and sulfasalazine. Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:1 Suppl Topics: Adolescent; Adult; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Re	2015
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6 Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents;	2015
Conventional DMARDs in axial spondyloarthritis: wishful--rather than rational--thinking! Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Female; Humans; Imm	2015
Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. The Journal of rheumatology, 2015, Volume: 42, Issue:8 Topics: Adult; Antirheumatic Agents; Etanercept; Female; Humans; Male; Middle Aged; Remission Induction; Spo	2015
Bilateral hip pain in a young man? It may be worth considering juvenile-onset ankylosing spondylitis (JAS). BMJ case reports, 2015, Oct-28, Volume: 2015 Topics: Adolescent; Anti-Inflammatory Agents; Arthritis, Juvenile; Hip Joint; Humans; Male; Methylprednisolo	2015
Sulfasalazine Treatment Suppresses the Formation of HLA-B27 Heavy Chain Homodimer in Patients with Ankylosing Spondylitis. International journal of molecular sciences, 2015, Dec-29, Volume: 17, Issue:1 Topics: Cytokines; Gene Expression; HLA-B27 Antigen; Humans; Leukocytes, Mononuclear; Protein Multimerizatio	2015
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine, 2016, Volume: 95, Issue:36 Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis	2016
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. International journal of rheumatic diseases, 2017, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib	2017
Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2017, Volume: 23, Issue:2 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Hyp	2017
M694V mutation may have a role in susceptibility to ankylosing spondylitis. Rheumatology international, 2009, Volume: 29, Issue:10 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diclofenac; Drug Combinations; Female; F	2009
Serum homocysteine level in patients with ankylosing spondylitis. Rheumatology international, 2009, Volume: 29, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Biomarkers; Blood Sedimentatio	2009
Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatology international, 2009, Volume: 29, Issue:12 Topics: Adult; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging;	2009
Anterior optic neuropathy, Roth spots, and ankylosing spondylitis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:6 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomethacin; Male;	2009
Assessment of soluble cell adhesion molecules and soluble CD40 ligand levels in ankylosing spondylitis. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Biomar	2010
The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint bone spine, 2011, Volume: 78, Issue:2 Topics: Absorptiometry, Photon; Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Mono	2011
Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis. Rheumatology international, 2012, Volume: 32, Issue:2 Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono	2012
Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy--experience from a tertiary care teaching hospital in South India. Clinical rheumatology, 2011, Volume: 30, Issue:7 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Drug Therapy, Combination; Female;	2011
Ankylosing spondylitis presented as unilateral optic neuritis in a young woman. Ocular immunology and inflammation, 2011, Volume: 19, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Color Vision; Drug Therapy, Combination;	2011
Acute myocardial infarction in a 56-year-old female patient treated with sulfasalazine. The American journal of emergency medicine, 2012, Volume: 30, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Electrocardiography; Fatal Outcome; Female; Humans; Middle	2012
Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication? Arthritis and rheumatism, 2011, Volume: 63, Issue:6 Topics: Antirheumatic Agents; Etanercept; Humans; Immunoglobulin G; Randomized Controlled Trials as Topic; R	2011
Sulphasalazine-induced aseptic meningitis with facial and nuchal edema in a patient with spondyloarthritis. International journal of rheumatic diseases, 2012, Volume: 15, Issue:4 Topics: Acyclovir; Anti-Inflammatory Agents; Antirheumatic Agents; Antiviral Agents; Drug Substitution; Drug	2012
Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience. International journal of rheumatic diseases, 2012, Volume: 15, Issue:6 Topics: Adult; Antirheumatic Agents; Biological Products; Biomarkers; Blood Sedimentation; C-Reactive Protei	2012
Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Annals of the rheumatic diseases, 2013, Volume: 72, Issue:7 Topics: Adult; Antirheumatic Agents; C-Reactive Protein; Controlled Clinical Trials as Topic; Etanercept; Fe	2013
Sulphasalazine-induced systemic lupus erythematous in a patient with ankylosing spondylitis. Clinical rheumatology, 2002, Volume: 21, Issue:4 Topics: Adult; Antirheumatic Agents; Humans; Lupus Erythematosus, Systemic; Male; Spondylitis, Ankylosing; S	2002
Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 Janua Annals of the rheumatic diseases, 2002, Volume: 61 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; C-Reactive Protein; Consensus; Foreca	2002
[A very late onset ankylosing spondylitis]. La Revue de medecine interne, 2003, Volume: 24, Issue:5 Topics: Age of Onset; Aged; Aged, 80 and over; Antirheumatic Agents; Blood Sedimentation; Female; Genotype;	2003
Late onset hypersensitivity to sulfasalazine in a patient with ankylosing spondylitis: comment on the article by Paul et al. Arthritis care and research : the official journal of the Arthritis Health Professions Association, 2000, Volume: 13, Issue:5 Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Drug Eruptions; Female	2000
Sensorineural hearing loss in a patient with ankylosing spondylitis. Rheumatology international, 2004, Volume: 24, Issue:4 Topics: Adult; Antirheumatic Agents; Hearing Loss, Sensorineural; Humans; Male; Spondylitis, Ankylosing; Sul	2004
Involvement of an inconstant bursa under the head of the second metatarsal bone in spondyloarthritis. Clinical rheumatology, 2004, Volume: 23, Issue:1 Topics: Adult; Antirheumatic Agents; Bursa, Synovial; Bursitis; Humans; Male; Metatarsal Bones; Metatarsopha	2004
Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report. Rheumatology international, 2005, Volume: 25, Issue:6 Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non	2005
Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clinical rheumatology, 2006, Volume: 25, Issue:2 Topics: Adult; Aged; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Lung; Male; Methotrexate; Mi	2006
Third-degree heart block developing in a female patient with HLA-B27 positive ankylosing spondylitis. Rheumatology international, 2006, Volume: 26, Issue:8 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Electrocardiography; Female; Follow-Up Studies; Hear	2006
Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug R	2006
Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug R	2006
Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug R	2006
Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. The Journal of rheumatology, 2006, Volume: 33, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug R	2006
Collagenous colitis and spondylarthropathy. Arthritis and rheumatism, 2006, Jun-15, Volume: 55, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Collagenous; Drug Therapy, Combination; Fem	2006
Intraarticular injection of infliximab. The Journal of rheumatology, 2006, Volume: 33, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Drug R	2006
Plasma homocysteine status in patients with ankylosing spondylitis. Clinical rheumatology, 2007, Volume: 26, Issue:5 Topics: Antirheumatic Agents; Case-Control Studies; Cross-Sectional Studies; Drug Therapy, Combination; Homo	2007
[Spondylarthritides]. Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:7 Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono	2006
Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease. Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:4 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Biopsy; Colon; Colonoscop	2006
Ankylosing spondylitis in a patient with Turner syndrome: a case report. Rheumatology international, 2007, Volume: 27, Issue:12 Topics: Adult; Antirheumatic Agents; Calcium; Combined Modality Therapy; Dietary Supplements; Exercise Thera	2007
Granulomatous ileitis in a patient with ankylosing spondylitis. Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4, Issue:6 Topics: Adult; Back Pain; Biopsy; Crohn Disease; Diagnosis, Differential; Gastrointestinal Agents; Humans; I	2007
[Main symptom: chronic deep back pain. Do you know the signs of Bechterew disease?]. MMW Fortschritte der Medizin, 2007, Jan-25, Volume: 149, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Humans; Low Back Pain; Methotrexat	2007
A new strategy of drug treatment in NSAID--unresponsive ankylosing spondylitis. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic;	2007
Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis? The Journal of family practice, 2007, Volume: 56, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Ps	2007
Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clinical rheumatology, 2008, Volume: 27, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Male; Methotrexate;	2008
Sulfasalazine and ankylosing spondylitis. Annals of internal medicine, 1984, Volume: 101, Issue:6 Topics: Adult; Female; Humans; Male; Spondylitis, Ankylosing; Sulfasalazine	1984
Macroscopic and histological changes of the ileum HLA-B27 related diseases: therapeutic consequences. International journal of clinical pharmacology research, 1984, Volume: 4, Issue:6 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Colonoscopy; HLA Antigens; HLA-B27 Antigen; Huma	1984
Should tests for proteinuria be included in the monitoring schedule of sulphasalazine? British journal of rheumatology, 1995, Volume: 34, Issue:8 Topics: Arthritis, Rheumatoid; Drug Monitoring; Female; Humans; Male; Middle Aged; Prevalence; Proteinuria;	1995
The spectrum of ankylosing spondylitis. Hospital practice (1995), 1995, Jul-15, Volume: 30, Issue:7 Topics: Adolescent; Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Diagnosis, Dif	1995
IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis. Annals of the rheumatic diseases, 1995, Volume: 54, Issue:8 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Bacterial; Antibody Sp	1995
Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scandinavian journal of rheumatology, 1994, Volume: 23, Issue:6 Topics: Adult; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Spondylitis,	1994
IgM, IgA and IgG class serum antibodies against Klebsiella pneumoniae and Escherichia coli lipopolysaccharides in patients with ankylosing spondylitis. British journal of rheumatology, 1994, Volume: 33, Issue:11 Topics: Antibodies, Bacterial; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Humans; Immunoglobulin A	1994
[Successful treatment with salazosulfapyridine in cases sister and brother with ankylosing spondylitis]. Ryumachi. [Rheumatism], 1993, Volume: 33, Issue:1 Topics: Adult; Drug Therapy, Combination; Family Health; Female; Humans; Male; Piroxicam; Spondylitis, Ankyl	1993
Changes in antinuclear serology in patients with spondylarthropathy under sulphasalazine treatment. British journal of rheumatology, 1993, Volume: 32, Issue:6 Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Cohort Studies; Female; Humans; Male; Middle Aged;	1993
Facial palsy and partial accommodative insufficiency associated with sulphasalazine treatment in a patient with ankylosing spondylitis. Scandinavian journal of rheumatology, 1993, Volume: 22, Issue:4 Topics: Accommodation, Ocular; Adult; Facial Paralysis; Humans; Male; Spondylitis, Ankylosing; Sulfasalazine	1993
Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scandinavian journal of clinical and laboratory investigation, 1996, Volume: 56, Issue:5 Topics: Adolescent; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Colitis, Ulcerative; Erythrocytes; Female	1996
Remission of a refractory nephrotic syndrome after low-density lipoprotein apheresis based on dextrane sulphate adsorption. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:5 Topics: Adsorption; Adult; Antirheumatic Agents; Blood Component Removal; Cholesterol; Dextran Sulfate; Huma	1997
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: comment on the article by Clegg et al. Arthritis and rheumatism, 1997, Volume: 40, Issue:10 Topics: Anti-Inflammatory Agents; Controlled Clinical Trials as Topic; Humans; Placebos; Spondylitis, Ankylo	1997
Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pacific journal of allergy and immunology, 1997, Volume: 15, Issue:2 Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Juvenile; Child; Chronic Disease; Female; Humans	1997
[Basic therapeutics in the management of various forms of arthritis]. Der Orthopade, 1998, Volume: 27, Issue:8 Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Humans; Methotrexate; Poly	1998
Sulphasalazine in the treatment of children with chronic arthritis. Clinical rheumatology, 1998, Volume: 17, Issue:5 Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Clinical Trials as T	1998
[Rheumatoid hyperthyroidism. Another observation]. Presse medicale (Paris, France : 1983), 1999, Jan-23, Volume: 28, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Glucosamine; Humans; Hyperthyroidi	1999
Late onset hypersensitivity to sulfasalazine in a patient with ankylosing spondylitis. Arthritis care and research : the official journal of the Arthritis Health Professions Association, 1999, Volume: 12, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Humans; Hypersensitivity, Del	1999
Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease. Annals of the rheumatic diseases, 2001, Volume: 60, Issue:8 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis; Arthritis	2001
Paravertebral abscess formation due to brucellosis in a patient with ankylosing spondylitis. Joint bone spine, 2001, Volume: 68, Issue:6 Topics: Abscess; Adult; Anti-Bacterial Agents; Brucella; Brucellosis; Diclofenac; Doxycycline; Drug Therapy,	2001
Ankylosing spondylitis and Behçet's disease in combination. Two case reports. Joint bone spine, 2002, Volume: 69, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Colchicin	2002
[Erythropoietin and hip surgery in an anemic Jehovah's Witness with ankylosing spondylitis, chronic liver disease, and Crohn's disease]. Revista espanola de anestesiologia y reanimacion, 2002, Volume: 49, Issue:2 Topics: Anemia, Hypochromic; Antirheumatic Agents; Autoimmune Diseases; Blood Loss, Surgical; Christianity;	2002
Ankylosing spondylitis. Current drug treatment. Drugs, 1992, Volume: 44, Issue:4 Topics: Adrenal Cortex Hormones; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Infla	1992
[Treatment of juvenile spondylarthritis and reactive arthritis with sulfasalazine]. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1992, Volume: 140, Issue:9 Topics: Adolescent; Arthritis, Juvenile; Arthritis, Reactive; Child; Dose-Response Relationship, Drug; Drug	1992
Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides. Annals of the rheumatic diseases, 1991, Volume: 50, Issue:6 Topics: Antibody-Producing Cells; Arthritis, Psoriatic; Arthritis, Rheumatoid; Enzyme-Linked Immunosorbent A	1991
No signs of Campylobacter jejuni/coli-related antibodies in patients with active ankylosing spondylitis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 1991, Volume: 99, Issue:8 Topics: Adult; Antibodies, Bacterial; Campylobacter jejuni; Enzyme-Linked Immunosorbent Assay; Female; Human	1991
[Osteoarticular manifestations of chronic inflammatory enterocolitis]. Annales de gastroenterologie et d'hepatologie, 1991, Volume: 27, Issue:3 Topics: Biopsy; Humans; Inflammatory Bowel Diseases; Spondylitis, Ankylosing; Sulfasalazine	1991
Evaluation of sulphasalazine in ankylosing spondylitis--an interventional study. British journal of rheumatology, 1990, Volume: 29, Issue:1 Topics: Adult; Blood Sedimentation; C-Reactive Protein; Female; Humans; Male; Middle Aged; Platelet Count; S	1990
A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. The Journal of rheumatology, 1990, Volume: 17, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cross-Sectional Studies; Diclofenac; F	1990
[Megaloblastic anemia caused by sulfasalazine in rheumatoid arthritis or ankylosing spondylitis?]. Medicina clinica, 1989, Jun-10, Volume: 93, Issue:2 Topics: Anemia, Macrocytic; Anemia, Megaloblastic; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Spondyl	1989
Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Clinical rheumatology, 1986, Volume: 5, Issue:1 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Arthritis; Bacterial Infections; Drug Evaluation; Drug	1986
Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and the influence of sulphasalazine treatment. Annals of the rheumatic diseases, 1987, Volume: 46, Issue:5 Topics: Adult; Blood Proteins; Eosinophil Granule Proteins; Eosinophils; Female; Humans; Inflammation; Male;	1987
Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment. Annals of the rheumatic diseases, 1988, Volume: 47, Issue:1 Topics: Acute-Phase Reaction; Adult; Aged; alpha 1-Antitrypsin; Arthritis, Rheumatoid; Blood Proteins; Femal	1988
T lymphocytes in ankylosing spondylitis and the influence of sulphasalazine treatment. Clinical rheumatology, 1987, Volume: 6, Issue:4 Topics: Adult; Antibodies, Monoclonal; Female; HLA-DR Antigens; Humans; Inflammation; Male; Middle Aged; Spo	1987
Perspectives in the aetiology of seronegative polyarthritis. British journal of rheumatology, 1988, Volume: 27 Suppl 2 Topics: Anti-Inflammatory Agents; Arthritis; Arthritis, Reactive; HLA Antigens; HLA-B27 Antigen; Humans; Spo	1988

sulfasalazine and Spondylitis, Ankylosing